Leila Khoja

Medicine & Life Sciences

1. Melanoma 100%
2. Circulating Neoplastic Cells 45%
3. pembrolizumab 35%
4. Survival 34%
5. Biomarkers 28%
6. Ipilimumab 25%
7. Uveal melanoma 24%
8. Skin 22%
9. Progression-Free Survival 22%
10. Prostatic Neoplasms 21%
11. Neoplasms 21%
12. Therapeutics 19%
13. Neoplasm Metastasis 18%
14. Cell- and Tissue-Based Therapy 17%
15. Eosinophilic Fasciitis 14%
16. cabozantinib 14%
17. Eye Neoplasms 14%
18. dabrafenib 14%
19. Response Evaluation Criteria in Solid Tumors 14%
20. Retinal Vasculitis 13%
21. Meta-Analysis 13%
22. Systematic Reviews 13%
23. Circulating Tumor DNA 13%
24. L-Lactate Dehydrogenase 12%
25. Neutrophils 11%
26. Esophagogastric Junction 11%
27. Tumor-Infiltrating Lymphocytes 11%
28. Phase II Clinical Trials 11%
29. Cell Count 10%
30. Castration 10%
31. Positron Emission Tomography Computed Tomography 9%
32. Benchmarking 9%
33. Androgen Receptors 9%
34. CTLA-4 Antigen 9%
35. Tumor Microenvironment 9%
36. Non-Small Cell Lung Carcinoma 9%
37. Phosphatidylinositol 3-Kinases 8%
38. Proteinuria 8%
39. Lymphocytes 8%
40. Drug Therapy 8%
41. Brain Diseases 8%
42. Ovarian Neoplasms 8%
43. Interleukin-2 8%
44. Glypicans 7%
45. Platinum 7%
46. Immunotherapy 7%
47. Cohort Studies 7%
48. Area Under Curve 7%
49. Hepatocellular Carcinoma 7%
50. Colorectal Neoplasms 7%